Please enable JavaScript or talk to your local administrator to get JavaScript enabled.

Project

Quantifying Risk and Resilience (R2) among Patients with Bladder Cancer: A Novel Personalized, Comprehensive Risk Stratification Program

Funder: Bladder Cancer Advocacy Network

Funding period
USD 50 K
Funding amount
Abstract
Background: Guidelines advocate for including a Comprehensive Geriatric Assessment (CGA) in the evaluation of elderly bladder cancer (BC) patients. To date, CGAs have not been studied in clinical pHypotheses: Integrating a comprehensive Risk and Resilience (R2) assessment in shared decision-making for localized BC will decrease decisional conflict and anxiety/depression, while improving generic health-related quality of life (HRQOL) and satisfaction with cancer-care satisfaction at treatment selection. Additionally, the R2 assessment will alter physicians’ subjective risk assessment and decrease physician-reported decisional-conflict score (DCS). Aims: 1)To compare changes in patient-reported decisional conflict and health-related quality of life among localized BC patients who completed the R2 assessment with those undergoing the usual risk assessment.2)To test the impact of the R2 assessment on provider’s subjective assessment of a patient’s fitness for definitive treatment for BC and physician-reported DCS after treatment selection. Methodologies: We will perform a prospective observational cohort study. Following informed consent, patients will receive standard of care risk assessment for 3 months and will serve as controls. Following treatment selection, patients will complete the DCS, PHQ-4 (anxiety and depression), QLQ-C30 and QLQ-BLM30 (HRQOL), and satisfaction with cancer care assessments; physicians will complete the DCS and render a subjective assessment of patients’ fitness for treatment. Patients being seen in months 4-11 will receive the R2 assessment. Patients and physicians will complete the outcome surveys as per above. Patient and physician-reported outcome measures will be compared between usual care and intervention cohorts. Concordance between physician risk assessment with/without the R2 score will be measured. This project responds to the BCAN PSN knowledge gaps in decision-making before definitive treatment of muscle-invasive BC.
Similar projects All >
Sorted by: Start Date
Project list item
Understanding the Burden and Impact of Financial Toxicity in Bladder Cancer: A Mixed Methods Study of 2 Diverse Patient Populations

Bladder Cancer Advocacy Network to Sumeet Kaur Bhanvadia, Reginald Tucker-Seeley, Siamak Daneshmand

USD 50,000
2019 - 2020
Project list item
Patient Empowerment through Engagement Research Training in Bladder Cancer PCOR (PEER)

Patient-Centered Outcomes Research Institute to Angela Smith

USD 249,524
2017 - 2018
Project list item
Novel Approach to Facilitate Decisions in Patients w/ Muscle Invasive Bladder CA

National Cancer Institute to MICHAEL A DIEFENBACH, MATTHEW GALSKY

USD 449,777
2015 - 2018
Project list item
Urodynamics for Prostate Surgery Trial; Randomised Evaluation of Assessment Methods (UPSTREAM) for diagnosis and management of bladder outlet obstruction in men

NIHR Evaluation Trials and Studies Coordinating Centre to Marcus Drake

USD 2,960,082
2014 - 2018

System

Categories
  • FOR (ANZSRC)

    1103 Clinical Sciences

  • FOR (ANZSRC)

    1112 Oncology and Carcinogenesis

  • FOR (ANZSRC)

    1117 Public Health and Health Services

  • RCDC

    Mental Health

  • RCDC

    Depression

  • RCDC

    Behavioral and Social Science

  • RCDC

    Cancer

  • RCDC

    Clinical Research

  • RCDC

    Patient Safety

  • RCDC

    Prevention

  • Health Research Areas

    Clinical

  • Broad Research Areas

    Health Services Research